RPE65 and Leber congenital amaurosis: RPE65-associated Leber congenital amaurosis, the disease with the first adeno-associated virus–based gene therapy treatment approved by the US Food and Drug Administration a genotype investigated in detail, has an estimated frequency of 1 in 576,667 individuals, with an estimated 7 new cases annually in the United States.42